Joshua Veatch

1.5k total citations
20 papers, 956 citations indexed

About

Joshua Veatch is a scholar working on Oncology, Immunology and Hematology. According to data from OpenAlex, Joshua Veatch has authored 20 papers receiving a total of 956 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 7 papers in Immunology and 3 papers in Hematology. Recurrent topics in Joshua Veatch's work include CAR-T cell therapy research (7 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Polyomavirus and related diseases (6 papers). Joshua Veatch is often cited by papers focused on CAR-T cell therapy research (7 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Polyomavirus and related diseases (6 papers). Joshua Veatch collaborates with scholars based in United States, South Africa and Austria. Joshua Veatch's co-authors include Daniel E. Gottschling, Michael A. McMurray, Anne E. Stellwagen, Stanley R. Riddell, Kelly G. Paulson, Matthew Fitzgibbon, Julia Kargl, A. McGarry Houghton, Shailender Bhatia and Sylvia M. Lee and has published in prestigious journals such as Cell, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Joshua Veatch

16 papers receiving 945 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joshua Veatch United States	9	587	319	192	191	114	20	956
Jean‐Yves Thuret France	15	843 1.4×	126 0.4×	179 0.9×	80 0.4×	24 0.2×	22	1.0k
Morgan E. Diolaiti United States	9	618 1.1×	300 0.9×	95 0.5×	256 1.3×	40 0.4×	20	977
Xu‐Rong Jiang United Kingdom	12	652 1.1×	238 0.7×	359 1.9×	239 1.3×	54 0.5×	17	1.1k
Yuchen Chien United States	5	730 1.2×	233 0.7×	411 2.1×	416 2.2×	62 0.5×	6	1.2k
Meta W. Djojosubroto Germany	7	402 0.7×	123 0.4×	357 1.9×	72 0.4×	94 0.8×	8	680
Hitomi Saso United States	9	773 1.3×	270 0.8×	60 0.3×	140 0.7×	112 1.0×	11	1.0k
Qingdong Deng United States	7	681 1.2×	239 0.7×	342 1.8×	122 0.6×	48 0.4×	8	920
Boris Shor United States	14	946 1.6×	272 0.9×	46 0.2×	151 0.8×	20 0.2×	16	1.3k
Özge Gürsoy-Yüzügüllü United States	12	1.0k 1.8×	240 0.8×	97 0.5×	80 0.4×	17 0.1×	12	1.2k
Ariel Pribluda Israel	7	688 1.2×	190 0.6×	90 0.5×	121 0.6×	20 0.2×	11	912

Countries citing papers authored by Joshua Veatch

Since Specialization

Citations

This map shows the geographic impact of Joshua Veatch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joshua Veatch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joshua Veatch more than expected).

Fields of papers citing papers by Joshua Veatch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joshua Veatch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joshua Veatch. The network helps show where Joshua Veatch may publish in the future.

Co-authorship network of co-authors of Joshua Veatch

This figure shows the co-authorship network connecting the top 25 collaborators of Joshua Veatch. A scholar is included among the top collaborators of Joshua Veatch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joshua Veatch. Joshua Veatch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Alvi, Mohammed Ali, et al.. (2025). Survival Correlates With Adjuvant Choice in Sentinel Node Positive Head and Neck Cutaneous Melanoma. The Laryngoscope. 135(10). 3670–3679.

Miller, Natalie J., Kevin Biese, Wenwen Chen, et al.. (2025). Trick-MCC: Final results from the proof-of-concept investigator-initiated study of combination therapy with anti–PD-1, anti–LAG-3, and anti–TIM-3 in participants with advanced or metastatic PD-(L)1 refractory Merkel cell carcinoma (NCT06056895).. Journal of Clinical Oncology. 43(16_suppl). 9531–9531.

Miller, Natalie J., Wenwen Chen, Evan Hall, et al.. (2024). TRICK-MCC: A proof-of-concept, investigator-initiated study of combination therapy with anti–PD-1, anti–LAG-3, and anti–TIM-3 in participants with advanced or metastatic PD-(L)1 refractory Merkel cell carcinoma.. Journal of Clinical Oncology. 42(16_suppl). TPS9618–TPS9618.

Goddard, Erica T., Miles H. Linde, Shivani Srivastava, et al.. (2024). Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies. Cancer Cell. 42(1). 119–134.e12. 29 indexed citations

Miller, Natalie, Jacob B. Leary, Joshua Veatch, et al.. (2023). 819 Concurrent treatment with GM-CSF immunoembolization of hepatic metastases and systemic immune checkpoint inhibitors to overcome immune evasion in patients with metastatic uveal melanoma. SHILAP Revista de lepidopterología. A917–A917.

Tachiki, Lisa, Daniel S. Hippe, Evan Hall, et al.. (2023). Extended duration of treatment using reduced-frequency dosing of anti-PD-1 therapy in patients with advanced melanoma and Merkel cell carcinoma. Cancer Immunology Immunotherapy. 72(11). 3839–3850. 9 indexed citations

Veatch, Joshua, Valentin Voillet, Cecilia C.S. Yeung, et al.. (2023). 768 Transcriptional profiling of Merkel cell carcinoma that escaped polyomavirus-specific TCR-engineered T cells reveals actionable immunotherapy approaches. SHILAP Revista de lepidopterología. A863–A863. 1 indexed citations

Sillah, Arthur, Ulrike Peters, Nathaniel F. Watson, et al.. (2022). Associating sleep problems with advanced cancer diagnosis, and immune checkpoint treatment outcomes: a pilot study. Supportive Care in Cancer. 30(5). 3829–3838. 1 indexed citations

Veatch, Joshua, Agus Darwanto, Sean T. Garrity, et al.. (2022). ATTAC-MCC: Phase I/II study of autologous CD8+ and CD4+ transgenic T cells expressing a high affinity MCPyV-specific TCR combined with checkpoint inhibitors and class I MHC-upregulation in patients with metastatic MCC refractory to PD-1 axis blockade.. Journal of Clinical Oncology. 40(16_suppl). TPS9596–TPS9596. 3 indexed citations

10.

Veatch, Joshua, Kelly G. Paulson, Evan Hall, et al.. (2022). Merkel polyoma virus specific T-cell receptor transgenic T-cell therapy in PD-1 inhibitor refractory Merkel cell carcinoma.. Journal of Clinical Oncology. 40(16_suppl). 9549–9549. 8 indexed citations

11.

Veatch, Joshua, Shivani Srivastava, Matthew Fitzgibbon, et al.. (2021). A therapeutic cancer vaccine delivers antigens and adjuvants to lymphoid tissues using genetically modified T cells. Journal of Clinical Investigation. 131(16). 17 indexed citations

12.

Sillah, Arthur, Scott S. Tykodi, Evan Hall, et al.. (2021). Predictive Lifestyle Markers for Efficacy of Cancer Immune Checkpoint Inhibitors: A Commentary. Future Oncology. 17(4). 363–369. 1 indexed citations

13.

Veatch, Joshua, et al.. (2020). Mobilization of pre-existing polyclonal T cells specific to neoantigens but not self-antigens during treatment of a patient with melanoma with bempegaldesleukin and nivolumab. Journal for ImmunoTherapy of Cancer. 8(2). e001591–e001591. 8 indexed citations

14.

Veatch, Joshua, Julia Kargl, Matthew Fitzgibbon, et al.. (2019). Endogenous CD4+ T Cells Recognize Neoantigens in Lung Cancer Patients, Including Recurrent Oncogenic KRAS and ERBB2 ( Her2 ) Driver Mutations. Cancer Immunology Research. 7(6). 910–922. 70 indexed citations

15.

Paulson, Kelly G., Deepti Gupta, Teresa S. Kim, et al.. (2019). Age-Specific Incidence of Melanoma in the United States. JAMA Dermatology. 156(1). 57–57. 151 indexed citations

16.

Veatch, Joshua, Sylvia M. Lee, Matthew Fitzgibbon, et al.. (2018). Tumor-infiltrating BRAFV600E-specific CD4+ T cells correlated with complete clinical response in melanoma. Journal of Clinical Investigation. 128(4). 1563–1568. 91 indexed citations

17.

Veatch, Joshua, Vicky Sandhu, Pamela S. Becker, et al.. (2013). The NCI common toxicity criteria and treatment-associated mortality in acute myeloid leukemia. Blood. 122(2). 293–294. 3 indexed citations

18.

Veatch, Joshua, Kathleen Shannon‐Dorcy, John M. Pagel, et al.. (2012). NCI Common Toxicity Criteria and Mortality After Chemotherapy for Acute Myeloid Leukemia (AML). Blood. 120(21). 1479–1479. 1 indexed citations

19.

Veatch, Joshua, et al.. (2009). Mitochondrial Dysfunction Leads to Nuclear Genome Instability via an Iron-Sulfur Cluster Defect. Cell. 137(7). 1247–1258. 333 indexed citations

20.

Stellwagen, Anne E., et al.. (2003). Ku interacts with telomerase RNA to promote telomere addition at native and broken chromosome ends. Genes & Development. 17(19). 2384–2395. 230 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact